AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Ivashchenko, Andrey A, Dmitriev, Kirill A, Vostokova, Natalia V, Azarova, Valeria N, Blinow, Andrew A, Egorova, Alina N, Gordeev, Ivan G, Ilin, Alexey P, Karapetian, Ruben N, Kravchenko, Dmitry V, Lomakin, Nikita V, Merkulova, Elena A, Papazova, Natalia A, Pavlikova, Elena P, Savchuk, Nikolay P, Simakina, Elena N, Sitdekov, Tagir A, Smolyarchuk, Elena A, Tikhomolova, Elena G, Yakubova, Elena V, Ivachtchenko, Alexandre V
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7454388/
https://ncbi.nlm.nih.gov/pubmed/32770240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa1176
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados